Publications by authors named "Miteshkumar Patel"

Article Synopsis
  • A phase 2 study showed that neoadjuvant treatment with dostarlimab, a PD-1 blocker, resulted in high rates of clinical complete response in patients with dMMR solid tumors, eliminating the need for surgery in many cases.
  • Among 117 patients, 84 demonstrated a clinical complete response, with a significant percentage opting for nonoperative management, leading to a recurrence-free survival rate of 92% over two years.
  • Most adverse events were mild and reversible, with 95% of patients experiencing grade 1 or 2 side effects, indicating that this approach is not only effective but also relatively safe.
View Article and Find Full Text PDF

N-methyladenosine (mA) is the most abundant internal RNA modification in eukaryotes and plays a key role in cellular growth and development. Global changes in cellular methylated RNA and mA-mediated transcript regulation significantly impact oncogenesis. Here, we investigate how recurrent synonymous and non-synonymous somatic mutations abolishing individual canonical methylated mA motifs affect transcript levels and survival of patients with cancer.

View Article and Find Full Text PDF

Purpose: The molecular drivers underlying mucinous tumor pathogenicity are poorly understood. mutations predict metastatic burden and treatment resistance in mucinous appendiceal adenocarcinoma. We investigated the pan-cancer clinicopathologic relevance of variants.

View Article and Find Full Text PDF
Article Synopsis
  • Neoadjuvant chemotherapy and radiation are standard treatments for locally advanced rectal cancer, particularly in cases with mismatch repair deficiency, which may respond well to PD-1 blockade therapy.
  • A phase 2 study was conducted using dostarlimab, an anti-PD-1 monoclonal antibody, to treat patients before typical chemoradiotherapy and surgery, with potential for some patients to skip the latter if they showed a complete response.
  • All 12 patients treated in the study displayed a clinical complete response with no tumor detected and no reported adverse effects of significant severity, indicating promising results for this approach.
View Article and Find Full Text PDF

Aortic aneurysms are life-threatening and often associated with defects in connective tissues and mutations in smooth muscle cell (SMC) contractile proteins. Despite recent advances in understanding altered signaling in aneurysms of Marfan syndrome, the underlying mechanisms and options for pharmacological treatment for other forms of aneurysms are still under investigation. We previously showed in mice that deficiency in the fibulin-4 gene in vascular SMCs (Fbln4(SMKO)) leads to loss of the SMC contractile phenotype, hyperproliferation, and ascending aortic aneurysms.

View Article and Find Full Text PDF